LOW ACTIVITY OF CIRCADIAN CONTINUOUS FLUORODEOXYURIDINE (FUDR) CHEMOTHERAPY IN POOR-PROGNOSIS METASTATIC RENAL-CANCER
- Authors:
- Published online on: January 1, 1994 https://doi.org/10.3892/or.1.1.121
- Pages: 121-123
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Thirteen patients with progressive metastatic renal cell carcinoma were treated with circadian continuous Fluorodeoxyuridine (FUDR) infusions. The drug was delivered according to the variable rate infusion of Hrushesky protocol. All patients had previously received and failed systemic treatment and presented more than one metastatic site. The toxicity was low, however, no objective responses were observed. Despite previous reports of activity of FUDR in metastatic renal cancer, we suggest that the present regimen cannot be recommended in poor prognosis metastatic renal cancer.